Compared to cytotoxic chemotherapies, the introduction of immunotherapy has changed the paradigm of treatment for patients with multiple myeloma, according to an expert. Dr. Dickran Kazandjian, a ...
Since the first checkpoint inhibitor was approved to treat melanoma in 2011, this type of immunotherapy has radically changed the lifespan of patients with metastatic melanoma, according to Dr. Jedd ...
PharmaJet needle-free technology can improve DNA vaccine delivery 1 and has been successfully adopted into multiple cancer vaccine development programs. Partner study data shows how PharmaJet ...
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy ...
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced ...
Roswell Park investigators will deliver 21 presentations on AI, immunotherapy, surgery and access to care at the AHNS ...
Patients with high-risk, locally advanced cervical cancer on IMMUNOCERV demonstrated increased tumor-infiltrating polyfunctional CD8+ (killer) T cells, and 1-year overall survival of 100% Data from ...
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics ...
KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (PVCT) today announced that data from preclinical research by Moffitt Cancer Center (“Moffitt”) on PV-10 (rose ...
ROS are key players in the immune system's response to infection and cancer, influencing how the body identifies and fights these threats. A balanced level of ROS supports healthy immune function, but ...
New data from the Phase 1b/2 trial of NOUS-209 in Lynch Syndrome (LS) carriers have been accepted for an oral presentation at the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results